High rates of deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) who have not achieved dmr after ≥1 year of prior imatinib (IMA) in the asciminib (ASC) monotherapy arm of the Phase 2 ASC4MORE study
Author:
Jorge Cortes,Giuseppe Saglio,Jan Geissler,Jiri Mayer,Gabriel Etienne,Michael Fillitz,Elvira Mora Casterá,Shruti Kapoor,Ana Paula Cardoso,Ugo Okoroji,Amila Sarac,Matthias Hoch,Sara Quenet,Timothy Hughes
Copyright © 2025 American Society of Hematology. Published by Elsevier Inc. All rights reserved. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.